Compare Stocks: LUCD, VSTM, BBOT, and IRWD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBOT BridgeBio Oncology Therapeutics	$8.86 -1.3%	$8.79	$7.00 ▼ $14.87	$719.96M	0.38	242,581 shs	152,532 shs
IRWD Ironwood Pharmaceuticals	$4.17 -2.1%	$4.18	$1.05 ▼ $5.78	$703.92M	0.2	1.57 million shs	2.28 million shs
LUCD Lucid Diagnostics	$0.90 -4.5%	$0.98	$0.86 ▼ $1.63	$190.95M	1.1	773,605 shs	961,103 shs
VSTM Verastem	$8.08 -1.5%	$6.36	$3.43 ▼ $10.82	$742.62M	0.32	1.87 million shs	4.37 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBOT BridgeBio Oncology Therapeutics	-1.34%	+0.45%	-5.04%	+24.44%	+885,999,900.00%
IRWD Ironwood Pharmaceuticals	-2.11%	-2.34%	-3.47%	+24.48%	+269.03%
LUCD Lucid Diagnostics	-4.54%	-7.94%	-7.27%	-11.21%	-27.09%
VSTM Verastem	-1.46%	+6.18%	+19.88%	+114.89%	-21.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBOT BridgeBio Oncology Therapeutics	$8.86 -1.3%	$8.79	$7.00 ▼ $14.87	$719.96M	0.38	242,581 shs	152,532 shs
IRWD Ironwood Pharmaceuticals	$4.17 -2.1%	$4.18	$1.05 ▼ $5.78	$703.92M	0.2	1.57 million shs	2.28 million shs
LUCD Lucid Diagnostics	$0.90 -4.5%	$0.98	$0.86 ▼ $1.63	$190.95M	1.1	773,605 shs	961,103 shs
VSTM Verastem	$8.08 -1.5%	$6.36	$3.43 ▼ $10.82	$742.62M	0.32	1.87 million shs	4.37 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBOT BridgeBio Oncology Therapeutics	-1.34%	+0.45%	-5.04%	+24.44%	+885,999,900.00%
IRWD Ironwood Pharmaceuticals	-2.11%	-2.34%	-3.47%	+24.48%	+269.03%
LUCD Lucid Diagnostics	-4.54%	-7.94%	-7.27%	-11.21%	-27.09%
VSTM Verastem	-1.46%	+6.18%	+19.88%	+114.89%	-21.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBOT BridgeBio Oncology Therapeutics	2.75	Moderate Buy	$24.40	175.40% Upside
IRWD Ironwood Pharmaceuticals	2.57	Moderate Buy	$6.23	49.48% Upside
LUCD Lucid Diagnostics	2.60	Moderate Buy	$4.19	366.94% Upside
VSTM Verastem	2.80	Moderate Buy	$13.83	71.20% Upside

Current Analyst Ratings Breakdown

Latest LUCD, VSTM, BBOT, and IRWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/4/2026	VSTM Verastem	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C+)
8/18/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	LUCD Lucid Diagnostics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.50
8/14/2026	BBOT BridgeBio Oncology Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$27.00 ➝ $25.00
8/10/2026	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$14.00 ➝ $13.00
8/7/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/7/2026	VSTM Verastem	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$14.00 ➝ $12.00
8/4/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/30/2026	IRWD Ironwood Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	$5.14 per share	N/A
IRWD Ironwood Pharmaceuticals	$296.15M	2.33	$0.25 per share	16.55	($1.61) per share	-2.59
LUCD Lucid Diagnostics	$4.71M	38.70	N/A	N/A	($0.31) per share	-2.89
VSTM Verastem	$30.91M	23.67	N/A	N/A	$0.74 per share	10.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBOT BridgeBio Oncology Therapeutics	-$134.04M	-$2.76	N/A	N/A	N/A	N/A	-46.90%	-42.17%	N/A
IRWD Ironwood Pharmaceuticals	$24.02M	$0.77	5.42	N/A	N/A	33.36%	-58.38%	34.93%	11/9/2026 (Estimated)
LUCD Lucid Diagnostics	-$58.01M	-$0.47	N/A	N/A	N/A	-959.76%	N/A	-119.57%	11/11/2026 (Estimated)
VSTM Verastem	-$209.47M	-$2.66	N/A	N/A	N/A	-231.59%	-467.49%	-94.54%	11/3/2026 (Estimated)

Latest LUCD, VSTM, BBOT, and IRWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	LUCD Lucid Diagnostics	-$0.0567	-$0.06	-$0.0033	-$0.08	$1.43 million	$1.47 million
8/11/2026	Q2 2026	BBOT BridgeBio Oncology Therapeutics	N/A	-$705.20	N/A	-$705.20	N/A	N/A
8/6/2026	Q2 2026	IRWD Ironwood Pharmaceuticals	$0.32	$0.31	-$0.01	$0.31	$114.84 million	$113.04 million
8/6/2026	Q2 2026	VSTM Verastem	-$0.4305	-$0.35	+$0.0805	-$0.35	$22.88 million	$40.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBOT BridgeBio Oncology Therapeutics	N/A	4.69	4.69
IRWD Ironwood Pharmaceuticals	N/A	6.06	6.06
LUCD Lucid Diagnostics	N/A	1.33	1.31
VSTM Verastem	1.48	2.25	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBOT BridgeBio Oncology Therapeutics	54.89%
IRWD Ironwood Pharmaceuticals	N/A
LUCD Lucid Diagnostics	74.01%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
BBOT BridgeBio Oncology Therapeutics	24.40%
IRWD Ironwood Pharmaceuticals	9.30%
LUCD Lucid Diagnostics	6.90%
VSTM Verastem	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBOT BridgeBio Oncology Therapeutics	N/A	80.17 million	60.61 million	N/A
IRWD Ironwood Pharmaceuticals	220	165.24 million	149.87 million	Optionable
LUCD Lucid Diagnostics	70	203.24 million	189.22 million	No Data
VSTM Verastem	50	90.56 million	88.81 million	Optionable

LUCD, VSTM, BBOT, and IRWD Headlines

Recent News About These Companies

Verastem Stock Skyrockets 121% in 3 Months: Here Is Why

September 8 at 11:11 AM | zacks.com

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

September 8 at 8:00 AM | businesswire.com

Verastem (NASDAQ:VSTM) Upgraded to Hold at Wall Street Zen

September 5, 2026 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Stock Rating Upgraded by Wall Street Zen

September 5, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Sees Strong Trading Volume - Should You Buy?

September 2, 2026 | marketbeat.com

Verastem Oncology to Participate in Upcoming September Investor Conferences

September 2, 2026 | businesswire.com

Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform

August 31, 2026 | seekingalpha.com

Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from Analysts

August 27, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Shares Down 8.6% - Should You Sell?

August 20, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Shares Up 6.4% - What's Next?

August 17, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

Verastem (VSTM) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Hennion & Walsh Asset Management Inc. Acquires 347,872 Shares of Verastem, Inc. $VSTM

August 12, 2026 | marketbeat.com

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Verastem Restructures Oberland Financing to Support Commercialization

August 7, 2026 | tipranks.com

Verastem, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

Verastem Reiterated as Buy on Strong AVMAPKI FAKZYNJA Momentum, VS-7375 Progress; $18 Price Target Maintained

August 7, 2026 | tipranks.com

Verastem: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

August 6, 2026 | finance.yahoo.com

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

Verastem’s TARGET-D 202 Trial Puts Fresh Focus on KRAS G12D Lung Cancer

July 30, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD, VSTM, BBOT, and IRWD Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

$8.86 -0.12 (-1.34%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$8.79 -0.07 (-0.79%)

As of 09/8/2026 07:30 PM Eastern

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

Ironwood Pharmaceuticals NASDAQ:IRWD

$4.17 -0.09 (-2.11%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$4.17 0.00 (-0.10%)

As of 09/8/2026 07:30 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Lucid Diagnostics NASDAQ:LUCD

$0.90 -0.04 (-4.54%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$0.92 +0.02 (+2.03%)

As of 09/8/2026 07:55 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Verastem NASDAQ:VSTM

$8.08 -0.12 (-1.46%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$8.18 +0.10 (+1.18%)

As of 09/8/2026 07:30 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LUCD, VSTM, BBOT, and IRWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LUCD, VSTM, BBOT, and IRWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LUCD, VSTM, BBOT, and IRWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD, VSTM, BBOT, and IRWD Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Ironwood Pharmaceuticals NASDAQ:IRWD

Lucid Diagnostics NASDAQ:LUCD

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LUCD, VSTM, BBOT, and IRWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LUCD, VSTM, BBOT, and IRWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LUCD, VSTM, BBOT, and IRWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD, VSTM, BBOT, and IRWD Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Ironwood Pharmaceuticals NASDAQ:IRWD

Lucid Diagnostics NASDAQ:LUCD

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools